A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder.

ABSTRACT: Gliosis is implicated in the pathophysiology of many neuropsychiatric diseases, including treatment-resistant major depressive disorder (TRD). Translocator protein total distribution volume (TSPO V_T), a brain marker mainly reflective of gliosis in disease, can be measured using positron emission tomography (PET). Minocycline reduces gliosis and translocator protein binding in rodents, but this is not established in humans. Here, the ability of oral minocycline to reduce TSPO V_T was assessed in TRD. To determine whether oral minocycline, as compared to placebo, can reduce prefrontal cortex (PFC), anterior cingulate cortex (ACC), and insula TSPO V_T in TRD, twenty-one TRD participants underwent two [¹⁸F]FEPPA PET scans to measure TSPO V_T.

SUBMITTER: Attwells S 

PROVIDER: S-EPMC8164633 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature